NIH Funding Freeze Delayed a Pediatric Brain Cancer Trial for Over a Year

A clinical trial testing an experimental mRNA-based approach for diffuse intrinsic pontine glioma, a nearly always fatal childhood brain cancer, was delayed for more than a year amid disruptions to National Institutes of Health funding, according to reporting that has tracked the broader fallout from the funding freeze across American research hospitals. The delay is one small piece of a much larger pattern documented by researchers who found that hundreds of active clinical trials were disrupted after federal grant funding was cut or frozen earlier in the year.

A report published in the journal JAMA Internal Medicine and covered by the Associated Press found that between the end of February and mid-August, funding ceased for 383 studies testing treatments for cancer, heart disease and brain disease, affecting more than 74,000 enrolled patients. Ars Technica reported that 118 of those cancelled trials involved cancer research in some form, and that patients already enrolled lost access to monitoring, medication or experimental treatment without warning. Forbes contributor coverage of the same JAMA study, published by Forbes, described the count as likely only the visible portion of a larger disruption, since many affected studies may not yet have been catalogued.

Officials describe efficiency while patients describe loss

Federal officials overseeing the funding decisions have generally framed cuts and pauses as efforts to eliminate duplication and focus limited resources on the most promising research, a framing that mirrors how the National Cancer Institute has periodically described its own portfolio decisions for pediatric brain tumour consortium funding. That framing sits uneasily next to accounts collected from patients and families whose treatment windows narrowed while funding questions were sorted out administratively.

The Guardian reported on Natalie Phelps, a 43-year-old mother with stage 4 colorectal cancer, who said her treatment start date slipped from mid-June to after mid-July because of the funding disruption, and whose case was raised in a congressional hearing involving Health Secretary Robert F. Kennedy Jr. Separately, ABC News reported that a major NIH immunotherapy trial led by Dr. Steven Rosenberg was thrown into a holding pattern after staff were laid off amid the freeze, and that the trial only resumed once the newly confirmed NIH director eased hiring and purchasing restrictions. Trial participant Melinda Bachini told ABC News that repeated stop-start funding created serious stress for patients waiting on access to treatment.

Questions remain about why decisions that officials describe as routine budget management produced such visible harm to people with terminal or advanced diagnoses, and whether the agencies involved have been forthcoming about how funding priorities were actually set during the freeze. The NIH and NCI have not published a detailed accounting of how individual trials, including pediatric brain tumour studies, were selected for delay or continuation, leaving families and outside researchers to piece together the effects from case reports and after-the-fact academic reviews.